Cardiovascular Health Status And Genetic Risk In Survivors of Childhood Neuroblastoma and Nephroblastoma Treated With Doxorubicin: Protocol of the Pharmacogenetic Part of the LESS-Anthra Cross-Sectional Cohort Study

Oliver Zolk   ^{1 *} , MD ;   Annika von dem Knesebeck   ^{2 *} , MD ;   Norbert Graf   ³ , MD ;   Thorsten Simon   ⁴ , MD ;   Barbara Hero   ⁴ , MD ;   Hashim Abdul-Khaliq   ⁵ , MD ;   Mohamed Abd El Rahman   ⁵ , MD ;   Claudia Spix   ⁶ , DPhil ;   Benjamin Mayer   ⁷ , PhD ;   Susanne Elsner   ⁸ , PhD ;   Judith Gebauer   ⁹ , MD ;   Thorsten Langer   ¹⁰ , MD

¹ Institute of Clinical Pharmacology, Brandenburg Medical School (Theodor Fontane), Immanuel Klinik Rüdersdorf, Rüdersdorf, Germany

² Institute of Pharmacology of Natural Products & Clinical Pharmacology, University of Ulm, Ulm, Germany

³ Department of Pediatric Oncology and Hematology, Saarland University, Homburg, Germany

⁴ Department of Pediatric Oncology and Hematology, Children's Hospital, University of Cologne, Cologne, Germany

⁵ Department of Pediatric Cardiology, Saarland University, Homburg, Germany

⁶ German Childhood Cancer Registry, Mainz, Germany

⁷ Institute of Epidemiology and Medical Biometry, University of Ulm, Ulm, Germany

⁸ Institute for Social Medicine and Epidemiology, University of Lübeck, Lübeck, Germany

⁹ Department of Internal Medicine I, University Hospital of Schleswig-Holstein, Lübeck, Germany

¹⁰ Department of Pediatric Oncology and Hematology, University Hospital for Children and Adolescents, Lübeck, Germany

*these authors contributed equally